Combination treatment of HCC with SBRT and immune checkpoint inhibition-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combination treatment of HCC with SBRT and immune checkpoint inhibition

Published:2023-12 Issue: Volume:192 Page:104191
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Podesta Christine,Kayani Mahaz^ORCID,Goody Rebecca,Samson Adel

Funder

University of Leeds

Cancer Research UK

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference79 articles.

1. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma;Abou-Alfa;N. Engl. J. Med.,2018

2. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma;Abou-Alfa;NEJM Evid.,2022

3. Anon, 2023 [Available from: 〈https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf〉.

4. Association of radiation therapy with risk of adverse events in patients receiving immunotherapy: a pooled analysis of trials in the us food and drug administration database;Anscher;JAMA Oncol.,2022

5. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer;Antonia;New Engl. J. Med.,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP